Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Oncol (R Coll Radiol) ; 18(6): 459-65, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16909969

RESUMO

AIMS: To determine the prognostic value of proliferative potential and DNA ploidy in 72 brain tumours (36 grade III and 36 grade IV astrocytomas) using bromodeoxyuridine (BrdUrd) incorporation and flow cytometry. MATERIAL AND METHODS: All 72 patients underwent excision, mostly incomplete of the tumour. After surgery, eight patients received conventionally fractionated radiotherapy, 11 patients received accelerated radiotherapy, and 53 patients received hypofractionated radiotherapy. Tumour samples taken during surgery from each patient were incubated in vitro for 1 h at 37 degrees C with BrdUrd using the high pressure oxygen method. The percentage of BrdUrd-labelled cells (BrdUrd labelling index [BrdUrd LI]), and the total DNA content were evaluated: RESULTS: The tumours showed variability in the BrdUrd LI values, which ranged from 0.3 to 19.1%. No difference was observed in mean BrdUrd LI between grade III and grade IV sub-groups. A significantly higher percentage of DNA aneuploidy was observed in grade III gliomas (69.4%) than in grade IV gliomas (52.8%). Univariate analysis showed that younger patients (< or = 51 years) (P = 0.021) with grade III gliomas (P = 0.030) and low tumour proliferation rate (BrdUrd LI < or = 2.7%, P = 0.028) had significantly higher 5-year survival rates. Tumour ploidy had no influence on patients' survival (P = 0.591). However, Cox multi-variate analysis showed that only age over 51 years, and high tumour proliferation rate (BrdUrd LI > 2.7%), were significant unfavourable prognostic factors in patient survival. CONCLUSION: In this study, independent prognostic factors for patients with high-grade gliomas treated with surgery and post-operative radiotherapy are age and tumour proliferation rate assessed according to the BrdUrd LI.


Assuntos
Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirurgia , Bromodesoxiuridina , Glioma/radioterapia , Glioma/cirurgia , Adulto , Fatores Etários , Idoso , Neoplasias Encefálicas/diagnóstico , Proliferação de Células/efeitos dos fármacos , Terapia Combinada , DNA de Neoplasias/análise , DNA de Neoplasias/efeitos dos fármacos , Progressão da Doença , Feminino , Citometria de Fluxo , Seguimentos , Glioma/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estadiamento de Neoplasias , Oxigênio/farmacologia , Ploidias , Prognóstico , Sensibilidade e Especificidade , Coloração e Rotulagem , Taxa de Sobrevida , Resultado do Tratamento , Células Tumorais Cultivadas
3.
Folia Histochem Cytobiol ; 36(3): 133-8, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9773297

RESUMO

The proliferative potential and DNA ploidy in 203 brain tumours (27 astrocytomas grade I, 37 grade II, 80 grade III, and 59 grade IV) were investigated using bromodeoxyuridine (BrdUrd) incorporation and flow cytometry. One to three tumour samples from each patient were incubated in vitro for one hour at 37 degrees C with bromodeoxyuridine (BrdUrd) using the high preasure oxygen method. After incubation, fixation and staining, the cell preparations were analysed by flow cytometry. The percentage of BrdUrd-labelled cells (BrdUrd Labelling Index, BrdUrdLI), the predicted potential doubling time (predTpot) and the total DNA content were evaluated. The percentage of unlabelled S-phase cells (SPF) and proliferative index (PI, the percentage of cells in S + G2 phases) were also estimated. DNA aneuploidy was found in 61.1% of high-grade (III-IV) and 50.0% of low-grade (I-II) astrocytomas. The tumours showed variability in the BrdUrdLI values which ranged from 0.2 to 15.8%. Significantly higher mean value for BrdUrdLI was shown in grade III-IV astrocytomas (3.4%), than in grade I-II astrocytomas (1.5%), p = 0.0068. Also significantly shorter mean predTpot was shown in high grade III-IV astrocytomas (28 days) than in low grade I-II tumours (51 days), p = 0.0096. However, no relationship was shown between other cell proliferation parameters and histological grade. The mean intratumoral variability calculated on the basis of BrdUrdLI values on 2-3 samples from each tumour amounted to 31.2% +/- SD 15.9%.


Assuntos
Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patologia , DNA/genética , Ploidias , Divisão Celular , Citometria de Fluxo , Humanos , Técnicas In Vitro , Prognóstico
4.
Pol J Pathol ; 49(4): 273-7, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-10323081

RESUMO

The aim of the study was to determine the survival of cells in the infiltration zone of the glia-derived primary tumors of the central nervous system and in the core of the tumor tissue with the use of immunocytochemical methods. According to the recent studies the proper functional relation of bcl-2 and bax proteins may play a major role in one of the possible pathways leading to cell survival or to cell death. From the point of view of the biological activity of a tumour the evaluation of cell population demonstrating the ability for survival is of importance for predicting tumour recurrence. We found that in the infiltration zone neurocytes and reactive glial cells had a strong expression of bcl-2 and weak expression of bax protein. Thus, we have concluded that the use of bcl-2 and bax can be a useful tool in the evaluation of survival activity of non-neoplastic cells in the infiltration zone and of the neoplastic cells within the tumour core. The latter cell populations can be regarded as germs responsible for tumour recurrence.


Assuntos
Glioma/química , Proteínas Proto-Oncogênicas c-bcl-2/análise , Proteínas Proto-Oncogênicas/análise , Neoplasias Supratentoriais/química , Adulto , Feminino , Glioma/patologia , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Estudos Retrospectivos , Neoplasias Supratentoriais/patologia , Proteína X Associada a bcl-2
5.
Folia Neuropathol ; 32(1): 21-30, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-7922099

RESUMO

In 16 patients with primary supratentorial and in 1 with cerebellar tumor among them 5 multiforme glioblastomas, 3 malignant astrocytomas, 6 astrocytomas of other subtypes and 1 mixed glioma (oligo-astrocytoma) the peripheral blood was drawn and lymphocytes were separated from it. Out of the removed part of the tumors about 10 cultures in each case were prepared and cultivated at least 14 days. When the growth zone was well developed the cultures were used for further studies. All samples of the separated lymphocytes activated with PHA were cultivated for 72 h. So prepared lymphocytes were added to the tumor culture in vitro and observed for 24 h. After that time the not adhered lymphocytes were removed and the remaining tissue cultures with adhered lymphocytes were fixed and stained and the number of lymphocytes was counted. It was found that 1 h after the addition of lymphocytes the number of lymphocytes was very high, though a great part of them did not adhere to the tumor tissue. After 24 h the number of adhered lymphocytes was small or minute. Taking into consideration the results obtained it seems that the low efficiency of therapy of gliomas with autologous lymphocytes in vivo can result from the very weak direct contact with tumor cells. The influence of lymphocytes can be very limited so more as the tumor cells can secret biological active substances like PGE2, which counteract the cytotoxic activity of lymphocytes. For that reason the number of lymphocytes can be of significant value as counterbalance to that properties of the tumor cells. Taking into account even secretion of tumor cells of the same biological active substances such as PGE2 which counteract the cytotoxic activity of lymphocytes for the efficient activity of lymphocytes the number of them may be of significant value.


Assuntos
Astrocitoma/patologia , Neoplasias Encefálicas/patologia , Encéfalo/patologia , Moléculas de Adesão Celular Neuronais/imunologia , Glioblastoma/patologia , Glioma/patologia , Ativação Linfocitária , Adulto , Astrocitoma/imunologia , Astrocitoma/ultraestrutura , Biomarcadores , Encéfalo/imunologia , Encéfalo/ultraestrutura , Neoplasias Encefálicas/imunologia , Canais de Cálcio/imunologia , Moléculas de Adesão Celular Neuronais/ultraestrutura , Técnicas de Cultura , Feminino , Glioblastoma/imunologia , Glioma/imunologia , Humanos , Imuno-Histoquímica , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/ultraestrutura , Masculino , Pessoa de Meia-Idade , Linfócitos T Citotóxicos/imunologia , Linfócitos T Citotóxicos/ultraestrutura
6.
Neurol Neurochir Pol ; 27(3): 367-73, 1993.
Artigo em Polonês | MEDLINE | ID: mdl-8232735

RESUMO

Preliminary results of prospective clinical study--49 adult patients with histologically proven anaplastic oligodendroglioma received postoperative radiotherapy. Patients were randomized to two treatment arms: Conventionally Fractionated Radiotherapy (CFR) and Large Fractionated Radiotherapy (LFR). In CFR group the whole brain was irradiated to the total dose of 50 Gy in 25 fractions over 5 weeks, then a 10 Gy "boost" in 5 fractions was delivered to the site of primary lesion in 5 days. In LFR group there were 3 courses of irradiation separated with one month interval. In each of the two first series the patients received 20 Gy in 5 fractions in five days to the whole brain, and in the third course, 10 Gy "boost" was delivered like in CFR regimen. The tolerance to treatment was good in both groups. Actuarial survival rates 2 and 4 years were 20% and 4% respectively for CFR group, and they were 27% and 0% respectively for LFR.


Assuntos
Neoplasias Encefálicas/radioterapia , Encéfalo/efeitos da radiação , Oligodendroglioma/radioterapia , Adulto , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/patologia , Feminino , Humanos , Masculino , Oligodendroglioma/diagnóstico , Oligodendroglioma/patologia , Estudos Prospectivos , Taxa de Sobrevida , Resultado do Tratamento
7.
Neurol Neurochir Pol ; Suppl 1: 116-21, 1992.
Artigo em Polonês | MEDLINE | ID: mdl-1407284

RESUMO

In the period from Jan 1 1984 to Dec 31 1990 clinical and radiological evidence of brain glioma was found in 120 cases treated previously surgically. The group comprised 55 women (46%) and 65 men (54%). At the time of tumour diagnosis their age was ranged 40 to 60 years. All patients received non-radical surgical treatment, supplemented with Co60 radiation in 104 cases, in 3 cases Co60 treatment was given together with chemotherapy (CCNU) and 12 patients received no complementary treatment. Thirty four patients (28%) had reoperations, in two cases even twice. In 86 cases (72%) treatment was palliative. Three types of secondary tumour regrowth were discerned. Reoperation prolonged survival and its effectiveness was greatest in regrowth type I. The shortest survival till the appearance of regrowth signs and the shortest survival after recurrence were in type II of regrowth.


Assuntos
Neoplasias Encefálicas/patologia , Glioma/patologia , Recidiva Local de Neoplasia/etiologia , Adulto , Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/cirurgia , Radioisótopos de Cobalto/administração & dosagem , Feminino , Glioma/diagnóstico por imagem , Glioma/mortalidade , Glioma/cirurgia , Humanos , Lomustina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/diagnóstico por imagem , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/cirurgia , Cuidados Pós-Operatórios , Reoperação , Fatores de Tempo , Tomografia Computadorizada por Raios X
8.
J Neurooncol ; 6(3): 285-91, 1988 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-3066856

RESUMO

A prospective, randomized trial evaluates the effects of two postoperative treatment regimens on survival in 198 adult patients with supratentorial gliomas. All patients were irradiated with 6,000 rads after possibly radical removal of tumors. CCNU administration in the doses of 100 mg/sq m of body surface every 6-8 weeks following surgery proved to have no significant effect on the survival of patients. The median survival time in patients receiving radiation therapy alone was 61 +/- 7 weeks, while in those receiving additional chemotherapy was 56 +/- 4 weeks. Tumor histological malignancy and patients age were found to be the only important prognostic factors, irrespective of the treatment modality.


Assuntos
Neoplasias Encefálicas/radioterapia , Glioma/radioterapia , Lomustina/uso terapêutico , Adolescente , Adulto , Idoso , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/cirurgia , Ensaios Clínicos como Assunto , Feminino , Glioma/tratamento farmacológico , Glioma/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Distribuição Aleatória
10.
Neurol Neurochir Pol ; 20(2): 137-42, 1986.
Artigo em Polonês | MEDLINE | ID: mdl-3774090

RESUMO

For estimating the effectiveness of combined treatment of cases of anaplastic gliomas of the cerebral hemispheres retrospective analysis was undertaken of 83 patients treated only surgically and prospective analysis of 81 patients treated by the combined method. In the group treated only surgically 47 patients had glioblastoma multiforme, and 36 had anaplastic oligodendroglioma. The general condition and the neurological status were evaluated using the score of Karnofsky. In the group of combined treatment the patients were given telegammatherapy from Co-60 cobalt source by the method of Skolyszewski and CCNU (Belustine) every 6-8 weeks for 1 year in doses of 100 mg/m2. In about 25% of patients transient leucopenia was observed, and 20% had transient thrombocytopenia. In about 30% of cases transient increase of intracranial pressure occurred. In the compared groups it was possible to establish, using the statistical method of representation probability of Kaplan-Meier and statistical analysis of Gehan as modified by Wilcoxon, that the mean survival time in the surgically treated patients was 6.25 months, while in the patients treated by combined method it was 13.97 months.


Assuntos
Neoplasias Encefálicas/terapia , Glioma/terapia , Encéfalo/cirurgia , Neoplasias Encefálicas/mortalidade , Radioisótopos de Cobalto/uso terapêutico , Terapia Combinada , Glioma/mortalidade , Humanos , Lomustina/uso terapêutico
11.
Neurol Neurochir Pol ; 14(5): 535-41, 1980.
Artigo em Polonês | MEDLINE | ID: mdl-6256674

RESUMO

In the years 1971 through 1977 247 patients with anaplastic cerebral gliomas were treated. Out of this material a group of 119 patients was completed who were treated only surgically and had follow-up examinations or responded to an inquiry form sent to them. In the light of this follow-up study it was established that the survival time was shortest, only up to 6 months, in the patients with preclinical symptoms lasting up to 3 months. In the remaining patients the survival time was longer, reaching over one year in 11 cases and over 2 years in 3 cases. In view of the mode of spread of recurrent neoplasm the authors differentiated exophytous expansion - with the infiltration filling the postoperative tissue defect and extending beyond its margins, infiltrative expansion - with the infiltration spreading on the walls of the postoperative tissue defect, destructive expansion - with the neoplasm infiltrating and destroying the brain tissue. Two latter modes of growth were most frequent and led to death of the patients without producing signs of intracranial hypertension.


Assuntos
Neoplasias Encefálicas/cirurgia , Glioma/cirurgia , Neoplasias Encefálicas/mortalidade , Seguimentos , Glioblastoma/cirurgia , Glioma/mortalidade , Humanos , Oligodendroglioma/cirurgia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA